Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cisplatin chemotherapy is standard for advanced bladder cancer but often fails due to chemoresistance.
• Identifying chemoresistance drivers is critical for improving patient prognosis.

Purpose of the Study:

• To identify novel molecular targets driving chemoresistance in bladder cancer.
• To investigate the role of latent transforming growth factor beta binding protein 1 (LTBP1) in bladder cancer chemoresistance.

Main Methods:

• Proteomics analysis of clinical bladder cancer tissues (cisplatin-naïve vs. resistant).
• Integration of Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets.
• LTBP1 knockdown experiments in bladder cancer cell lines.
• In vivo studies using subcutaneous tumor and lung metastasis mouse models.

Main Results:

• Latent transforming growth factor beta binding protein 1 (LTBP1) identified as a potential chemoresistance gene.
• LTBP1 expression correlates with advanced clinical stage and poorer patient survival.
• LTBP1 knockdown inhibited bladder cancer cell proliferation, migration, invasion, and chemoresistance via TGF-β signaling.
• Combined LTBP1 inhibition and cisplatin treatment significantly reduced tumor growth and metastasis in mouse models.

Conclusions:

• LTBP1 plays a significant role in promoting bladder cancer progression and chemoresistance.
• LTBP1 is a potential therapeutic target for overcoming cisplatin resistance in bladder cancer.
• Targeting LTBP1 may improve treatment efficacy and patient outcomes in advanced bladder cancer.